VISEN Pharmaceuticals (HKG:2561)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
44.80
-2.00 (-4.27%)
May 28, 2025, 4:08 PM HKT
-34.88%
Market Cap 5.10B
Revenue (ttm) 123.40M
Net Income (ttm) -189.10M
Shares Out 113.93M
EPS (ttm) -20.24
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 60,200
Average Volume 40,075
Open 46.35
Previous Close 46.80
Day's Range 44.75 - 46.75
52-Week Range 39.25 - 69.15
Beta n/a
RSI 40.88
Earnings Date n/a

About VISEN Pharmaceuticals

VISEN Pharmaceuticals, an investment holding company, engages in the development and commercialization of endocrine therapies in the People’s Republic of China, Hong Kong, and Taiwan. Its lead product, Lonapegsomatropin, is a once-weekly long-acting growth hormone replacement therapy for the treatment of pediatric growth hormone deficiency. The company also develops TransCon CNP (navepegritide), a long-acting prodrug of c-type natriuretic peptide for the treatment of achondroplasia; and Palopegteriparatide, a once-daily parathyroid hormone repl... [Read more]

Sector Healthcare
Founded 2018
Country Cayman Islands
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2561
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements

News

There is no news available yet.